Summary
The provided AI claims are primarily about drug pricing, coupons/assistance, and patent landscape rather than memantine and donepezil extended-release capsule labeling content. None of these non-label topics are supported or contradicted by the supplied FDA label excerpts; therefore label alignment cannot be established and may mislead users.
Category Scores
Accurate Statements
Unsupported Statements
Without insurance, the average retail price for a 30-day supply of memantine immediate-release tablets can range from approximately $300 to over $400.
Not supported by the provided FDA label excerpts; label excerpts contain no pricing information. Also, the label provided is for memantine and donepezil hydrochlorides extended-release capsules, not memantine immediate-release tablets.
Memantine prices can vary depending on dosage, formulation, insurance coverage, and pharmacy.
Not supported by the provided FDA label excerpts; label excerpts contain no statements about pricing determinants.
Generic versions of memantine are available and typically cost less than brand-name formulations.
Not supported by the provided FDA label excerpts; label excerpts contain no statements about generic availability or relative cost.
The specific memantine strength and quantity prescribed affect overall expense.
Not supported by the provided FDA label excerpts; label excerpts contain no statements about how prescribed strength/quantity affects expense.
Higher milligram strengths or larger bottle sizes may carry a higher unit price.
Not supported by the provided FDA label excerpts; label excerpts contain no pricing guidance.
Different pharmacies can charge different markups or offer different discounts, affecting memantine cost.
Not supported by the provided FDA label excerpts; label excerpts contain no pharmacy markup/discount statements.
Comparing prices across different pharmacies, including online options, can reveal savings on memantine.
Not supported by the provided FDA label excerpts; label excerpts contain no instructions or claims about price comparison or online pharmacies.
Discount cards or coupon programs can lower out-of-pocket expenses for memantine.
Not supported by the provided FDA label excerpts; label excerpts contain no discussion of coupons/discount cards.
Insurance plans can affect out-of-pocket cost for memantine based on co-pay or co-insurance.
Not supported by the provided FDA label excerpts; label excerpts contain no insurance/cost-sharing statements.
Some insurance plans may place memantine in a formulary tier with a specific co-pay.
Not supported by the provided FDA label excerpts; label excerpts contain no formulary tier/cost-sharing statements.
Some insurance plans may require prior authorization for memantine before covering its cost.
Not supported by the provided FDA label excerpts; label excerpts contain no prior authorization statements.
Patient assistance programs sponsored by pharmaceutical manufacturers may be available for eligible individuals who cannot afford memantine.
Not supported by the provided FDA label excerpts; label excerpts contain no patient assistance program statements.
U.S. Patent No. 5,061,721, related to the use of memantine in treating neurodegenerative diseases, has expired.
Not supported by the provided FDA label excerpts; label excerpts contain no patent status information.
DrugPatentWatch.com tracks patent information and exclusivity periods for pharmaceuticals.
Not supported by the provided FDA label excerpts; label excerpts contain no discussion of external patent-tracking resources.
The patent landscape for memantine includes multiple patents covering the drug and its uses.
Not supported by the provided FDA label excerpts; label excerpts contain no patent landscape statements.
Memantine coupons can reduce the out-of-pocket cost for the medication.
Not supported by the provided FDA label excerpts; label excerpts contain no coupon statements.
Memantine coupons are often provided by third-party discount card programs or directly by pharmaceutical companies.
Not supported by the provided FDA label excerpts; label excerpts contain no coupon program sourcing statements.
Memantine coupons can be beneficial for individuals without insurance or whose insurance plans have high co-pays for memantine.
Not supported by the provided FDA label excerpts; label excerpts contain no coupon/insurance/cost statements.
The terms and conditions of a memantine coupon must be checked to ensure it applies to the specific formulation and dosage.
Not supported by the provided FDA label excerpts; label excerpts contain no coupon terms/coverage guidance.
Generic memantine contains the same active ingredient as the brand-name drug.
Not supported by the provided FDA label excerpts; label excerpts contain no statements about generic formulation equivalence.
Generic memantine works in the same way as the brand-name drug.
Not supported by the provided FDA label excerpts; label excerpts contain no generic-to-brand mechanism equivalence statements.
Generic memantine is subject to the same quality and safety standards as the brand-name drug.
Not supported by the provided FDA label excerpts; label excerpts contain no generic quality/safety equivalence statements.
Generic memantine is typically manufactured and sold at a significantly lower price after patents on the brand-name drug have expired.
Not supported by the provided FDA label excerpts; label excerpts contain no statements about post-patent pricing.
Common side effects associated with memantine include dizziness.
Not supported as stated for the supplied label product. The label excerpt’s 'most common adverse reactions with memantine hydrochloride extended-release' are headache, diarrhea, and dizziness. However, the AI did not specify it is for memantine hydrochloride extended-release and the overall product labeling provided is for 'memantine and donepezil hydrochlorides extended-release capsules'; the claim is not precisely aligned to the label wording/context.
Common side effects associated with memantine include headache.
Partially supported by the label excerpt ('most common adverse reactions with memantine hydrochloride extended-release… were headache, diarrhea, and dizziness'), but the AI did not anchor to 'memantine hydrochloride extended-release' within the provided combination product label context. Marked unsupported due to imprecision.
Common side effects associated with memantine include confusion.
Not supported by the provided FDA label excerpts for the 'most common adverse reactions' section. No statement in the provided excerpts lists confusion as a common adverse reaction for memantine hydrochloride extended-release.
Common side effects associated with memantine include constipation.
Not supported by the provided FDA label excerpts; constipation is not listed among the 'most common adverse reactions with memantine hydrochloride extended-release' (headache, diarrhea, dizziness).
Common side effects associated with memantine include drowsiness.
Not supported by the provided FDA label excerpts; drowsiness is not listed among the 'most common adverse reactions with memantine hydrochloride extended-release' (headache, diarrhea, dizziness).
Less common but more serious side effects can occur with memantine use.
Not supported specifically by the provided FDA label excerpts as phrased; while the label includes adverse reactions and warnings, the provided excerpts do not support this general statement with the described 'less common but more serious' framing.
Contradictions
Low
AI Statement
The provided FDA label pertains to memantine immediate-release tablets (implied by 'memantine immediate-release tablets' pricing claim).
Label Reference
Label excerpts provided are for 'memantine and donepezil hydrochlorides extended-release capsules' (INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, DOSAGE FORMS AND STRENGTHS).
Important Omissions
Safety Assessment
Potential Patient Risk:
High
The claims emphasize cost/coupon/patent information not present in the provided FDA label excerpts and include multiple adverse-effect assertions not supported by the label excerpted adverse-reaction list. The imprecision/mismatch of product (memantine immediate-release vs the provided combination extended-release capsule label) increases risk of misleading users.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are outside the scope of the supplied FDA label excerpts (pricing, coupons/assistance, insurance mechanics, and patent landscape). Several adverse-reaction claims (confusion, constipation, drowsiness) are not supported by the provided label excerpt.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label excerpts (e.g., indication, dosing regimen, contraindications, specified warnings/precautions, and the label’s listed 'most common' adverse reactions for memantine hydrochloride extended-release). Remove or clearly separate non-label topics (pricing, coupons, insurance requirements, patents) from label-based statements.